Annovis Bio falls on planned $50 mln share sale

Annovis Bio

11/12/2024 12:32

** Drug developer Annovis Bio's  ANVS.N  shares fall 4.6% to
$5.40 premarket
    ** ANVS files for up to $50 mln "at-the-market" stock sale
agreement to be handled by Oppenheimer 
    ** Co plans to use the proceeds for general corporate
purposes, including the development of its lead experimental
drug buntanetap       
    ** ANVS set to host its year-end investor webcast late
Wednesday    
    ** ANVS has 13.8 mln outstanding shares and $78 mln market
capitalization - LSEG data    
    ** As of last close, ANVS shares down 69.7% YTD


 (Reporting by Arasu Kannagi Basil in Bengaluru)
 ((ArasuKannagi.Basil@thomsonreuters.com;))